HomeAI · summaries
Storia in 4 fonti
J&J lines up $2.58B option to buy Sail, Flagship's in vivo CAR-T biotech
J&J pays $785M upfront to partner with Flagship's Sail Biomedicines on in vivo CAR-T for autoimmune diseases, with option to acquire Sail for $2.58B more.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Sail Biomedicines Announces Strategic Collaboration to Develop New Class of Medicines for In Vivo CAR-T
Sail Biomedicines Announces Strategic Collaboration to Develop New Class of Medicines for In Vivo CAR-T
- ·
biopharmadive.com
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
The deal with the buzzy Flagship Pioneering-backed startup makes J&J the latest large drugmaker to bet that the technology might be able to treat autoimmune conditions.
